JANX News and Press, Janux Therapeutics Inc. From 02/10/24

2024-02-10 14:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today an...

2023-12-15 15:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-13 07:12:15 ET Summary Janux Therapeutics is a biotech focused on developing novel immunotherapeutic approaches for cancer patients. Their lead candidate, JANX007, is a tumor-activated T-cell engager that targets PSMA in prostate cancer. Janux also has two other molecu...

2023-11-16 03:13:26 ET More on Janux Therapeutics Seeking Alpha’s Quant Rating on Janux Therapeutics Historical earnings data for Janux Therapeutics Financial information for Janux Therapeutics For further details see: Janux Therapeutics up ~4%, CF...

2023-11-08 09:20:03 ET More on Janux Therapeutics Seeking Alpha’s Quant Rating on Janux Therapeutics Historical earnings data for Janux Therapeutics For further details see: Janux Therapeutics GAAP EPS of -$0.25

Janux Therapeutics Inc. (JANX) is expected to report $-0.46 for Q3 2023

Enrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer Enrollment ongoing for EGFR-TRACTr (JANX008) in solid tumors Update on clinical programs expected in 2024 $349.7 million in cash, cash equivalents, and short-term investments at end of third quarter 2023 ...

2023-08-09 13:06:36 ET Janux Therapeutics press release ( NASDAQ: JANX ): Q2 GAAP EPS of -$0.42. Revenue of $1.05M (-55.5% Y/Y). For further details see: Janux Therapeutics GAAP EPS of -$0.42, revenue of $1.05M

Presented positive interim Phase 1 clinical trial data for PSMA-TRACTr JANX007 in prostate cancer Management team bolstered with key appointment $303.3 million in cash, cash equivalents, and short-term investments at end of second quarter 2023 In July, further strengthened...